Roche ditches dalcetrapib, due to disappointing trial results

Kaitlyn Dmyterko | | Cardiovascular Business | Structural Heart Disease
drugs - 186.00 Kb
After underwhelming results, Roche has pulled its second analysis of the dalcetrapib dal-OUTCOMES Phase III trial after the Data and Safety Monitoring Board (DSMB) pinpointed the trial's “lack of clinically meaningful efficacy.”

The trial aimed to evaluate the efficacy and safety of dalcetrapib when it was added to standard care in patients with stable coronary heart disease after acute coronary syndrome. Dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, works to increase high density lipoprotein cholesterol (HDL-C) levels in plasma by preventing the transport of HDL-C to very low-density lipoprotein/low-density lipoprotein.

Basel, Switzerland-based Roche said it will stop all six trials in the dal-HEART program: dal-OUTCOMES, dal-OUTCOMES 2, dal-PLAQUE 2, dal-ACUTE, dal-PLAQUE and dal-VESSEL.

No safety signals have been reported by the DSMB relating to the dal-OUTCOMES trial.

“Lowering cardiovascular risk beyond that which is achieved with intensive statin treatment is a very challenging goal and while we have always stated that dalcetrapib is a high-risk project, we are disappointed by the fact that this drug didn't provide benefit to the patients in our study,” said Hal Barron MD, chief medical officer and head of global product development, in a statement. He added that the company remained committed to developing new medicines for people with cardiovascular disease.

Kaitlyn Dmyterko

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."